Previous close | 9.85 |
Open | 9.53 |
Bid | 9.50 x 0 |
Ask | 9.60 x 0 |
Day's range | 9.51 - 9.75 |
52-week range | 7.03 - 9.85 |
Volume | |
Avg. volume | 8,123 |
Market cap | 110.175M |
Beta (5Y monthly) | 0.95 |
PE ratio (TTM) | 16.40 |
EPS (TTM) | 0.58 |
Earnings date | 20 Aug 2024 - 26 Aug 2024 |
Forward dividend & yield | 0.18 (1.89%) |
Ex-dividend date | 31 May 2024 |
1y target est | 9.65 |
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. (“BioSyent Pharma”), has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada. BioSyent Pharma and its European partner have agreed to seek Health Canada approval of the product by the end of 2024. “We are
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...
The board of BioSyent Inc. ( CVE:RX ) has announced that it will pay a dividend of CA$0.045 per share on the 15th of...